Eldelumab
Based on 1 Customer Validation
Eldelumab (BMS-936557; MDX-1100) is a fully human IgG1 monoclonal antibody targeting IP-10 (CXCL10). Eldelumab binds and neutralizes IP-10, blocking TNF-α induction, disruption of endothelial junctional complexes, integrin activation, and activated T cell migration. Eldelumab selectively reduces TNF-α release in infected endothelial cells and restores Claudin5, Occludin, ZO-1, and VE-Cadherin expression. Eldelumab can be used for research on hand, foot, and mouth disease (HFMD) and ulcerative colitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.50%
- CAS. Nr.: 946414-98-8
- Molecular Weight:146.64 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Isotype
Human IgG1(K214R) kappa
Recommend Isotype Controls
Species Reactivity
Human
|
IP-10 (CXCL10) |
TNF-α |
Claudin5 |
Occludin |
ZO-1 |
VE-Cadherin |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Scratch/Wound-Healing Migration Assay
- RNA extraction experimental
- Cell migration
- Neural Crest/Neuronal Cell Migration Explant Assay
- Research Protocol for Cancer Immunology
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- DSS-Induced Colitis
- Transwell/Boyden Chamber Migration Assay
- TNBS-Induced Colitis
- Endothelial Tube Formation Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IP-10/CXCL10 Protein can bind Eldelumab. The EC50 for this effect is 1.68 ng/mL.
Chemical Information
-
CAS. Nr. 946414-98-8
-
Appearance Liquid
-
Molecular Weight 146.64 kDa
-
Color Colorless to light yellow
-
SMILES
[Eldelumab]
-
Synonyms
BMS-936557; MDX-1100
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Eldelumab
- 946414-98-8
- BMS-936557
- MDX-1100
- BMS936557
- BMS 936557
- MDX1100
- MDX 1100
- MDX-1100
- CXCR
- TNF Receptor
- CXC chemokine receptors
- C-X-C motif chemokine receptors
- Tumor Necrosis Factor Receptor
- TNFR
- CXCL10
- Claudin5
- Occludin
- T-cell migration
- TNF-α
- VE-Cadherin
- ZO-1
- endothelial junctional complex
- hand
- foot and mouth disease
- ulcerative colitis
- Inhibitor
- inhibitor
- inhibit